Search
This JAK3A572V knockin model is a relevant new tool for testing the efficacy of JAK inhibitors in JAK3-related hematopoietic malignancies
New collaborative research involving almost 600,000 pregnant mothers has demonstrated a dramatic increase in uptake of the whooping cough (pertussis) vaccine after identifying just 22 per cent of WA women had the maternal vaccination between 2012 – 2017.
Babies worldwide could have access to life-saving influenza vaccinations from just eight weeks of age thanks to researchers at The Kids Research Institute Australia and the generous support of the Telethon community.
Infectious disease researchers who used a decade of scientific evidence to advocate for a nationwide childhood influenza immunisation policy have earned a finalist position at the country’s most prestigious science awards – the Australian Museum Eureka Prizes.
News headlines about the large number of life-threatening cases of the flu in Western Australia this winter have been hard to miss - find out what you can do to protect your family.
Perth parents are underestimating the serious consequences of the flu, with only 19 per cent of children under five years of age currently immunized against the virus ahead of the peak winter flu season.
A new research project aims to demonstrate how influenza vaccination in children could be a highly cost-effective health care intervention in Australia.
It's that time of year again... Flu vaccine time! Watch Dr Chris Blyth answer commonly asked questions in the video below.
Influenza vaccine effectiveness and immunogenicity can be compromised with repeated vaccination. We assessed immunological markers in a cohort of healthcare workers (HCW) from six public hospitals around Australia during 2020-2021.
The nasal epithelium is the primary point of contact for inhaled respiratory viruses such as rhinovirus, respiratory syncytial virus, influenza, and coronavirus, among others. In order to establish infection, these viruses must engage their respective receptors located on host epithelial cells and begin replication.
SARS-CoV-2 nucleocapsid (N) protein antibodies can be used to identify the serological response to natural infection in those who have previously received a COVID-19 spike-based vaccine. Anti-N antibody responses can also be induced by inactivated whole SARS-CoV-2 virus vaccines, such as CoronaVac. We aimed to characterise antibody responses to the N protein following COVID-19 and following vaccination with CoronaVac.